| Target Molecule | ACTH (1-10), human |
| Synonyms | Adrenocorticotropic Hormone Fragment 1-10, (1-10)-Corticotropin, ACTH (1-10) (human, rat) |
| CAS Number | 2791-05-1 |
| Sequence (3-Letter) | H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-OH |
| Sequence (1-Letter) | SYSMEHFRWG |
| Molecular Formula | C₅₉H₇₈N₁₆O₁₆S |
| Molecular Weight | 1299.4 |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥95%, ≥98% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate, TFA, or custom salt options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) and Scavenger-Protected Cleavage |
| Modification Options | Stable isotope labeling (13C, 15N), fluorescent/biotin tagging, fragment cascade synthesis (ACTH 1-24, ACTH 1-39) |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and extended regulatory documentation provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
ACTH (1-10), human (CAS 2791-05-1) is a 10-amino acid peptide (SYSMEHFRWG) representing the N-terminal core of adrenocorticotropic hormone. We target this sequence to supply high-purity reference standards, analytical calibration markers, and raw materials for melanocortin pathway research.
We utilize optimized solid-phase peptide synthesis (SPPS) protocols. Because the sequence contains oxidation-prone Met4 and reactive Trp9, our peptide synthesis platform applies specialized scavenger cocktails and inert gas handling during cleavage to suppress side reactions and deliver exceptional purity.
Yes. We provide specialized peptide modification services for ACTH (1-10). Options include site-specific stable isotope labeling (such as 13C and 15N) for quantitative LC-MS/MS, N-terminal fluorescent and biotin tagging, and the intentional preparation of oxidation reference standards.
Our manufacturing infrastructure scales production from milligram-level analytical batches to multigram and kilogram commercial quantities. We optimize preparative HPLC purification and controlled counter-ion exchange (such as TFA removal to acetate) to ensure strict batch-to-batch consistency.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, impurity profiling, analytical method validation, and regulatory documentation to accelerate complex drug development pipelines.
ACTH (1-10), human (CAS 2791-05-1) is a 10-residue peptide defined by the sequence SYSMEHFRWG. It contains the central pharmacophore of the melanocortin receptor system. Synpeptide provides comprehensive custom synthesis solutions for this target molecule, delivering analytical-grade reference standards and raw materials for pharmacokinetic profiling and assay development.
Synthesizing peptides containing both methionine and tryptophan requires precise control to prevent oxidation and alkylation artifacts during cleavage. Our custom peptide synthesis platform utilizes optimized Solid-Phase Peptide Synthesis (SPPS) methodologies. By deploying targeted scavenger systems and inert atmosphere cleavage protocols, we preserve sensitive side chains and isolate ACTH (1-10) at high purity levels (typically ≥95% or ≥98% via HPLC) for rigorous analytical calibration.
Quantitative mass spectrometry (LC-MS/MS) of peptide metabolites in biological matrices requires chemically identical internal standards. Through our peptide modification services, we synthesize stable-isotope-labeled ACTH (1-10) incorporating heavy amino acids (such as 13C and 15N labeled Phe or Val). We also provide terminal modifications, fluorescent labels, and biotin conjugates to facilitate receptor binding kinetics and enzymatic degradation tracking.
When reference standards or metabolic fragments are integrated into high-throughput screening programs, supply consistency is vital. We execute large-scale peptide synthesis for ACTH (1-10) and related cascade fragments. Our scalable preparative HPLC infrastructure and validated counter-ion exchange protocols ensure that materials are delivered with consistent salt forms (including TFA-removed and acetate options) from milligram research batches to kilogram commercial supply.
We provide full structural verification and analytical documentation as an integrated peptide CDMO. Our technical specialists assist pharmaceutical and diagnostic developers with analytical method validation, impurity identification, and stability profiling across related sequences, including ACTH (1-24). Every batch is released with complete documentation—including COA, HPLC purity traces, and exact mass confirmation—ensuring regulatory alignment for preclinical research.
